IMNN Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

Imunon Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerIMNN

Market Cap9.2M

Cash RunwayRunway < 6 months

Next Catalystn/a

Public Research Snapshot

Imunon Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for IMNN-001 (Phase 1) using Vaccine.

Pipeline

Asset	Indication	Modality	Stage	Public Note
What's New	n/a	Vaccine	n/a	Public pipeline row
IMNN-001	n/a	n/a	Phase 1	Public pipeline row
IMNN-101	n/a	n/a	Phase 1	Public pipeline row
IMNN-201	n/a	Vaccine	n/a	Public pipeline row

Catalyst Preview

No public catalyst rows matched this view yet.

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
No public trial rows are loaded yet.

Scientific Context

literature_publication | A novel surname-based methodology to improve the disaggregation of Asian American ethnic subgroups in patients with ovarian cancer.
literature_publication | Paraneoplastic pemphigus in primary peritoneal clear cell carcinoma: a multidisciplinary management approach.
literature_publication | Correlation of patient reported outcomes and physical exam screening for pelvic floor dysfunction: An opportunity for improved quality of life during chemoradiotherapy for cervical cancer.
literature_publication | Mitoredox shifts in mitochondrial dysfunction.
literature_publication | Safe and durable immune responses to a single dose DNA COVID-19 vaccine in previously vaccinated or SARS-CoV-2-infected adults: A phase 1 study.

Want the full IMNN research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.